Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.88 |
| ▸ | KRAS | P01116 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | TNFRSF1A | P19438 | 5/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.71 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.71 |
| ▸ | TUBB | P07437 | 3/20 | 0.71 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.71 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.71 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.71 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.71 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.71 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.71 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.71 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.71 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.71 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659039 | 1.00 | ABCG2 (0.88) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL31059028 | 0.88 | ABCG2 (0.69) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL31059037 | 0.88 | ABCG2 (0.69) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL31059020 | 0.88 | ABCG2 (0.69) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL615818 | 0.88 | KRAS (1.00) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL13018517 | 0.88 | KRAS (1.00) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL6780730 | 0.88 | ABCG2 (0.88) | ABCG2KRASTNFRSF1AABCB1TUBB1 | |
| SCHEMBL10497922 | 0.88 | ABCG2 (0.88) | ABCG2KRASLMNAMAPTMAPK1 | |
| SCHEMBL6780724 | 0.88 | ABCG2 (0.88) | ABCG2KRASTNFRSF1AABCB1TUBB1 | |
| SCHEMBL1425775 | 0.88 | MAPT (0.81) | ABCG2KRASLMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090603-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8598366-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8269017-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20060217389-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2006-09-28 | — | — | US | disclosed |
| WO-2006089177-A2 | ISOXAZOLE COMBRETASTIN DERIVATIVES FOR THE TREATMENT OF DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1051383-B1 | HYDROXYLATION ACTIVATED PRODRUGS | UNIV MONTFORT (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-6677383-B1 | SUPRRESION OF TUMORS CONTAINING OXIDOREDUCTASE ENZYMES, BY CONTACTING THE CELLS WITH ANTITUMOR CHEMICAL INTERMEDIATES SUCH AS 3,4,5-TRIMETHOXY-4'-METHOXYSTILBENE | DE MONTFORT UNIVERSITY (GB) | 2004-01-13 | — | — | US | disclosed |
| US-6346550-B2 | TYROSINE KINASE INHIBITOR; ANTITUMOR AGENT | DE MONTFORT UNIVERSITY (GB) | 2002-02-12 | — | — | US | disclosed |
| US-20010021717-A1 | Hydroxylation activated prodrugs | DE MONTFORT UNIVERSITY | 2001-09-13 | — | — | US | disclosed |
| US-6214886-B1 | INHIBITING GROWTH OF TUMOR CELLS VIA STYRENE-DERIVED PRODRUGS WHICH ARE ACTIVATED BY ACTIVITY OF A HYDROXYLASE | DEMONTFORT UNIVERSITY, THE GATEWAY (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-1051383-A1 | HYDROXYLATION ACTIVATED PRODRUGS | DE MONTFORT UNIVERSITY (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999040056-A1 | HYDROXYLATION ACTIVATED PRODRUGS | DE MONTFORT UNIVERSITY (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ABCG2 664/4885KRAS 63/4885LMNA 2274/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ABCG2 664/4885KRAS 63/4885LMNA 2274/4885 |
| US-20010021717-A1 | Hydroxylation activated prodrugs | CYP1B1, CYP1A1, CYP1A2 | ABCG2 299/4885KRAS 1072/4885LMNA 4058/4885 |
| US-20060217389-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | ABCG2 664/4885KRAS 63/4885LMNA 2274/4885 |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ABCG2 664/4885KRAS 63/4885LMNA 2274/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ABCG2 664/4885KRAS 63/4885LMNA 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.